Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges

K. Parikh, L.E.L. Hendriks, P. Bironzo, J. Remon*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

2 Citations (Web of Science)

Abstract

Malignant pleural mesothelioma (MPM) is a rare and orphan thoracic malignancy, with a poor prognosis as the majority of patients are diagnosed with unresectable MPM, with no significant improvements in the therapeutic strategy for over a decade. However, the recent approval of immune checkpoint inhibitors (ICI) in treatment naive patients with unresectable MPM marks a significant step forward and hope for the treatment of this disease. In this narrative review, we discuss the biological rationale to use ICI in the treatment of MPM. We summarize the current evidence for the efficacy of ICI in MPM and discuss several unresolved challenges regarding the use of ICI in this disease, such as the best upfront immune approach in MPM (ICI versus ICI plus chemotherapy), the optimal sequential treatment strategy according to the first-line treatment, and the potential role of predictive biomarkers.
Original languageEnglish
Article number102250
Number of pages8
JournalCancer Treatment Reviews
Volume99
DOIs
Publication statusPublished - 1 Sep 2021

Keywords

  • Mesothelioma
  • Immune checkpoint inhibitors
  • Nivolumab
  • Pembrolizumab
  • Ipilimumab
  • MALIGNANT PLEURAL MESOTHELIOMA
  • PHASE-II TRIAL
  • OPEN-LABEL
  • SINGLE-ARM
  • PLUS IPILIMUMAB
  • T-CELLS
  • CHEMOTHERAPY
  • MULTICENTER
  • NIVOLUMAB
  • SAFETY

Cite this